摘要
报告了应用本科研制的^(131)I-AFP McAb对肝癌RII 33例和RIT 24例,给予的^(131)I-AFP McAb量分别为RII:74～185MBq/IgG 0.1-1mg;RIT:740～2960 MBq/IgG 0.5～5mg,治疗前后检测肝、肾功能,白细胞计数,临床观察给药后有无反应。分析结果33倒RII病人,给药后未见不良反应。24例RIT病人,治疗前后白细胞及肝、肾功能未见显著变化,3例病人出现畏寒,发抖,呼吸急促,心悸等输液反应,持续10～15min后消失,少数病例出现恶心,呕吐和发热。1例患者在二年内共应用4次,均未见不良反应,还讨论了McAb应用后的抗抗体及过敏反应,以及今后改进等问题。
Radioimmunoimaging (RⅡ) and radioimmunotherapy (RIT) using 131I-AFP McAb were performed on 33 and 24 hepatoma patients, respectively. The dosages given were 74-185 MBq/IgG 0.1-1 mg for RⅡ and 740-2960 MBq/IgG 0.5-5 mg for RIT. No adverse effects were seen in the 33 cases receiving RⅡ. In the 24 cases receiving RIT, no significant changes were observed in the number of leukocytes, the hepatic arid renal function before and after the treatment. However, chillness, tachypnea and palpitation were noted in three patients, which persisted 15 min and were due to pyrogen reaction of infusion. A few cases had nausea, slight vomiting and a rise in temperature. One patient received four courses of treatment within a period of two years without any adverse effect. The problem of anti-antibody and anaphylactic reaction was also discussed in the paper.
关键词
放射免疫显像
治疗
抗甲胎蛋白
radibimmunoimaging
radioimmunothergapy
alphafetoprotein
antibody,monoclonal
